News

Semler Scientific signals aggressive bitcoin acquisition strategy with $500M ATM program while managing healthcare headwinds
Semler Scientific's Q1 2025 earnings call reveals an aggressive bitcoin acquisition strategy alongside efforts to diversify healthcare offerings ...
Acumen targets ALTITUDE-AD Phase 2 topline results in late 2026 while advancing subcutaneous Sabirnetug development
CEO Dan O'Connell reported that Acumen completed enrollment of its 542-participant Phase 2 ALTITUDE-AD study evaluating Sabirnetug for early Alzheimer’s disease, stating, "We completed enrollment of ...